White House Pulls Fda Pick Over Lack Of Support
The Trump administration is pulling Heidi Overton’s nomination to lead the Food and Drug Administration because it lacks sufficient support in the Senate, a White House official confirmed Tuesday night.
The Senate Health, Education, Labor and Pensions Committee was scheduled to vote Wednesday morning on Overton, who’s currently deputy director of the White House’s Domestic Policy Council, focusing on health policy. Committee Chair Bill Cassidy (R-La.) late Tuesday challenged the notion that Overton didn’t have the votes, saying in a social media post that the administration “abandoned a viable confirmation path” and that he’d had “productive conversations” with colleagues.
“I believe she would have had the votes to pass out of committee and pass the full Senate,” Cassidy wrote in a post on the social media platform X, signaling Overton also had won his support.
But anti-abortion senators, Cassidy added, “sought final assurances” about the White House’s “commitment to life issues.”
“The Administration withdrew Dr. Overton rather than make such commitments,” he said.
But earlier Tuesday, Sen. Josh Hawley — a staunch abortion opponent who had questioned Overton sharply about the administration’s ongoing safety review of abortion pills — said he’d secured pledges from the nominee that satisfied him.
The White House didn’t immediately respond to a request for comment on Cassidy’s remarks.
Axios first reported that Overton’s nomination would be pulled.
Leaders in the Make America Healthy Again movement, who had accused Overton of undermining their goals as a Trump aide, celebrated the nomination’s demise Tuesday night.
“God sent a rainbow after the storm,” Turning Point USA’s Alex Clark posted on X.
“Another one bites the dust,” said Vani Hari, an ally of Health Secretary Robert F. Kennedy Jr. who goes by “Food Babe” to her online followers.
Several GOP senators told reporters this week they remained undecided on Overton’s nomination, including Cassidy. Susan Collins of Maine and Lisa Murkowski of Alaska said they were still communicating with Overton on Tuesday on issues of concern.
While there were few fireworks during her September nomination hearing, several Republicans key to Overton’s advancement previously signaled they weren’t sold by her performance. She declined to say how she would regulate abortion pills if confirmed. She touted the safety and efficacy of the measles, mumps and rubella vaccine despite President Donald Trump’s statements suggesting the shot is deadly, but she skirted senators’ questions about how she’d maintain political independence at the public health agency.
Since then, former Trump administration aide Calley Means has publicly accused her of undermining Health Secretary Robert F. Kennedy Jr.’s Make America Healthy Again agenda — specifically tying her to efforts to help pesticide makers avoid liability claims over their products and to block psychedelic drug therapies from advancing toward FDA approval. Kennedy has called Overton “the best person for the job.”
Senior White House officials, including chief of staff Stephen Miller, discussed over the weekend whether to pull Overton and put in a replacement, according to four people with knowledge of the matter and granted anonymity to discuss it. Republicans suggested Sen. Roger Marshall, who lost his reelection bid in Kansas, as a possible replacement.
Kennedy met with Marshall, chair of the congressional MAHA Caucus, in recent days to discuss the role, said one person familiar with the conversation, who was granted anonymity to speak candidly.
When contacted by POLITICO Sunday night, the White House said it was not considering Marshall for the role.
Trump officials also worried that Sen. Ron Johnson (R-Wis.), an ally of MAHA’s so-called medical freedom wing, would have placed a hold on Overton’s nomination to block or delay a floor vote, according to two of the four people with direct knowledge of the situation.
Some in the pharmaceutical industry believed Overton would have provided the steady leadership needed for the FDA’s career experts to make regulatory calls unimpeded by politics.
Former Republican FDA Commissioners Scott Gottlieb and Mark McClellan — who sit on the boards of Pfizer and Johnson & Johnson, respectively — made the point in a September op-ed endorsing Overton. They also said they expected her to advance policies to address the competitive rise of China’s biotech sector.
PhRMA and the Biotechnology Innovation Organization had avoided publicly commenting on the pick — which isn’t atypical, since drugmakers will have to work with whoever ends up in the commissioner’s office. But one industry executive said earlier Tuesday that Overton’s lack of industry and regulatory experience — plus her ties to former FDA Commissioner Marty Makary, who came under fire for his approach to some rare-disease drug applications — had sparked concern among company leaders about how she’d lead the agency.
“There are many in industry who would feel far more comfortable with someone who has spent time on the other side and has proven they are willing to be flexible and prioritize American interests,” the executive, who was granted anonymity to speak candidly, said.
An industry lobbyist, granted anonymity to speak candidly, suggested Overton imperiled her chances when she stood by Trump as he signed an executive order calling for the measles, mumps and rubella vaccine to be split into separate shots.
“Now we have headlines saying we’re not ‘measles-free,’ we're ‘measles-full,’” the lobbyist added, nodding to Tuesday’s announcement that the U.S. has lost its measles elimination status.
Former Trump health official Chris Meekins, now a health care analyst at Raymond James, said the White House’s insistence on putting Overton forward as its FDA nominee “was a silly unforced error,” given widespread concerns about how she’d lead the agency responsible for regulating products that account for about one-fifth of U.S. consumer spending.
“There will not be a permanent commissioner any time soon,” he said. “That inevitably creates uncertainty at an agency desperately needing consistent permanent leadership to restore confidence of the public, staff and industry.”
Kennedy, despite voicing support for Overton’s nomination, appeared to be unconcerned about that prospect.
At a recent private reception, the health secretary said he doesn’t expect Democrats to vote for any Trump administration health nominees once they take control of Congress, according to a video of his speech shared by the organizer on X.
This could allow the Trump administration to keep an acting commissioner in charge of the agency, meaning, Kennedy said, that he would no longer need to secure support for his nominees from Senate Republicans, whom he said had throttled his agenda in the past.
“Every time I tried to do something robust, I would get calls [from GOP senators] saying, ‘If you do that, we’re not going to confirm your appointees,’” Kennedy said last week, speaking at a reception organized by MAHA Action, an advocacy group that supports his agenda.
“The Senate no longer has any leverage over me, and that’s a big deal,” Kennedy said.
Ben Johansen and Cheyenne Haslett contributed to this report.
Popular Products
-
Gas Detector Meter$311.56$155.78 -
Foldable Garbage Picker Grabber Tool$93.56$46.78 -
Portable Unisex Travel Urinal$49.56$24.78 -
Reusable Keychain Pepper Spray – 20ml$21.56$10.78 -
Camping Survival Tool Set$41.56$20.78